Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.

Beguin Y, Selleslag D, Meers S, Graux C, Bries G, Deeren D, Vrelust I, Ravoet C, Theunissen K, Voelter V, Potier H, Trullemans F, Noens L, Mineur P.

Acta Clin Belg. 2015 Feb;70(1):34-43. doi: 10.1179/2295333714Y.0000000102. Epub 2014 Dec 2.

2.

Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.

Meers S, Selleslag D, Potier H, Glasmacher A, Mineur P, Voelter V.

Curr Med Res Opin. 2015 Jan;31(1):35-42. doi: 10.1185/03007995.2014.972499. Epub 2014 Oct 17.

PMID:
25317956
3.

MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial.

Romano E, Michielin O, Voelter V, Laurent J, Bichat H, Stravodimou A, Romero P, Speiser DE, Triebel F, Leyvraz S, Harari A.

J Transl Med. 2014 Apr 12;12:97. doi: 10.1186/1479-5876-12-97.

4.

Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.

Kim K, Kim SJ, Voelter V, Suh C, Yoon SS, Lee JJ, Kwak JY, Ryoo HM, Kim YS, Moon JH, Park SK, Kim SH, Mun YC, Kim JS, Eom HS, Jo DY, Jun HJ, Kim KH, Lee JO, Lee JH, Min CK; Korean Multiple Myeloma Working Party (KMMWP).

Ann Hematol. 2014 Jan;93(1):113-21. doi: 10.1007/s00277-013-1893-z. Epub 2013 Sep 12.

PMID:
24026427
5.

(18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.

Orcurto V, Denys A, Voelter V, Schalenbourg A, Schnyder P, Zografos L, Leyvraz S, Delaloye AB, Prior JO.

Melanoma Res. 2012 Feb;22(1):63-9. doi: 10.1097/CMR.0b013e32834d3dcb.

6.

Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients.

Speiser DE, Schwarz K, Baumgaertner P, Manolova V, Devevre E, Sterry W, Walden P, Zippelius A, Conzett KB, Senti G, Voelter V, Cerottini JP, Guggisberg D, Willers J, Geldhof C, Romero P, Kündig T, Knuth A, Dummer R, Trefzer U, Bachmann MF.

J Immunother. 2010 Oct;33(8):848-58. doi: 10.1097/CJI.0b013e3181f1d614.

PMID:
20842051
7.

Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients.

Laurent J, Speiser DE, Appay V, Touvrey C, Vicari M, Papaioannou A, Canellini G, Rimoldi D, Rufer N, Romero P, Leyvraz S, Voelter V.

J Immunother. 2010 Sep;33(7):723-34. doi: 10.1097/CJI.0b013e3181ea7e6e.

PMID:
20664354
8.

Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.

Wieckowski S, Baumgaertner P, Corthesy P, Voelter V, Romero P, Speiser DE, Rufer N.

J Immunol. 2009 Oct 15;183(8):5397-406. doi: 10.4049/jimmunol.0901460. Epub 2009 Sep 28.

9.

Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time.

Iancu EM, Corthesy P, Baumgaertner P, Devevre E, Voelter V, Romero P, Speiser DE, Rufer N.

J Immunol. 2009 Jul 1;183(1):319-31. doi: 10.4049/jimmunol.0803647.

10.

Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor.

Voelter V, Rufer N, Reynard S, Greub G, Brookes R, Guillaume P, Grosjean F, Fagerberg T, Michelin O, Rowland-Jones S, Pinilla C, Leyvraz S, Romero P, Appay V.

Int Immunol. 2008 Aug;20(8):1087-96. doi: 10.1093/intimm/dxn066. Epub 2008 Jun 23.

PMID:
18573812
11.

Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma.

Voelter V, Diserens AC, Moulin A, Nagel G, Yan P, Migliavacca E, Rimoldi D, Hamou MF, Kaina B, Leyvraz S, Hegi ME.

Int J Cancer. 2008 Sep 1;123(5):1215-8. doi: 10.1002/ijc.23632.

12.

Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.

Voelter V, Schalenbourg A, Pampallona S, Peters S, Halkic N, Denys A, Goitein G, Zografos L, Leyvraz S.

Melanoma Res. 2008 Jun;18(3):220-4. doi: 10.1097/CMR.0b013e32830317de.

PMID:
18477897
13.

An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain.

Voelter V, Pica A, Laurent J, Rimoldi D, Bouzourene H, Sajadi A, Matter M, Romero P, Rufer N, Speiser DE.

Cancer Immun. 2008 Mar 27;8:6. No abstract available.

14.

Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen.

Speiser DE, Baumgaertner P, Voelter V, Devevre E, Barbey C, Rufer N, Romero P.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3849-54. doi: 10.1073/pnas.0800080105. Epub 2008 Mar 4. Erratum in: Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10632.

15.

In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration.

Derré L, Bruyninx M, Baumgaertner P, Devevre E, Corthesy P, Touvrey C, Mahnke YD, Pircher H, Voelter V, Romero P, Speiser DE, Rufer N.

J Immunol. 2007 Aug 15;179(4):2368-79.

16.

Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.

Appay V, Voelter V, Rufer N, Reynard S, Jandus C, Gasparini D, Lienard D, Speiser DE, Schneider P, Cerottini JC, Romero P, Leyvraz S.

J Immunother. 2007 Feb-Mar;30(2):240-50.

PMID:
17471171
17.

CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II.

Voelter V, Zouhair A, Vuilleumier H, Matter M, Bouzourene H, Leyvraz S, Bauer J, Coucke P, Stupp R.

Br J Cancer. 2006 Sep 18;95(6):710-6. Epub 2006 Aug 29.

18.

New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.

Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, Lienard D, Guillaume P, Krieg AM, Cerottini JC, Romero P, Leyvraz S, Rufer N, Speiser DE.

J Immunol. 2006 Aug 1;177(3):1670-8.

19.

Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.

Abbrederis K, Bassermann F, Schuhmacher C, Voelter V, Busch R, Roethling N, Sendler A, Siewert JR, Peschel C, Lordick F.

Ann Thorac Surg. 2006 Jul;82(1):293-7.

PMID:
16798232
20.

Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.

Baumgaertner P, Rufer N, Devevre E, Derre L, Rimoldi D, Geldhof C, Voelter V, Liénard D, Romero P, Speiser DE.

Cancer Res. 2006 Feb 15;66(4):1912-6.

21.

Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients.

Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, Bosshard W, Fiorentini G, Lotem M, Weitzen R, Keilholz U, Humblet Y, Piperno-Neumann S, Stupp R, Leyvraz S.

Ann Oncol. 2006 Apr;17(4):578-83. Epub 2006 Feb 9.

PMID:
16469752
22.

Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples.

Appay V, Reynard S, Voelter V, Romero P, Speiser DE, Leyvraz S.

J Immunol Methods. 2006 Feb 20;309(1-2):192-9. Epub 2005 Dec 27.

PMID:
16403411
23.

[Breaking bad news].

Voelter V, Mirimanoff RO, Stiefel F, Rousselle I, Leyvraz S.

Rev Med Suisse. 2005 May 18;1(20):1350, 1352-3. Review. French.

PMID:
15991627
24.

Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer.

Voelter V, Schuhmacher C, Busch R, Peschel C, Siewert JR, Lordick F.

Ann Thorac Surg. 2004 Sep;78(3):1037-41.

PMID:
15337044
25.

Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.

Sotiropoulou PA, Perez SA, Voelter V, Echner H, Missitzis I, Tsavaris NB, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2003 Dec;52(12):771-9. Epub 2003 Sep 10.

PMID:
13680193
26.

Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu-positive epithelial tumours.

Sotiropoulou PA, Perez SA, Iliopoulou EG, Missitzis I, Voelter V, Echner H, Baxevanis CN, Papamichail M.

Br J Cancer. 2003 Sep 15;89(6):1055-61.

27.

Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal carcinoma: a phase I study.

Voelter V, Stupp R, Matter M, Gillet M, Bouzourene H, Leyvraz S, Coucke P.

Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1288-94.

PMID:
12873673

Supplemental Content

Loading ...
Support Center